Clinical Trial Update: Trial of Kuvan in Lesch-Nyhan Disease [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial of Kuvan for behavioral manifestations in Lesch-Nyhan disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lesch-nyhan Disease

Drugs mentioned

• KUVAN (Sapropterin dihydrochloride)

Snippet

Sponsor: University of California, San Diego | Conditions: Behavioral Manifestations of Lesch-Nyhan Disease | Phase 2, Phase 3 | Status: WITHDRAWN